Dan joined the company in 2011. Before joining Lumanity, Dan worked in Research and Development for Takeda Europe, leading the pre-, peri-, and post-launch health economics and outcomes research (HEOR) planning for diabetes and obesity compounds. He has led the development of cost-effectiveness models and health technology assessment (HTA) submissions, providing strategic guidance on HEOR and market access. Dan achieved a PhD investigating the dynamic impact of health difficulties in adolescence on the formation of valued abilities and skills. Dan works with the HEOR Board to develop and articulate strategic direction.